From Cancer Communicator
News & Analysis
Conference coverage, FDA updates, clinical trial analysis, and more.
-
Aspiring doctors may need to find another quarter million dollars to go to school
Workforce access · Federal student loan reform Aspiring doctors may need to find another quarter million dollars to go to school. The federal funding…
-
ASCO GU 2026: Perioperative EV/Pembrolizumab Outperforms Gemcitabine/Cisplatin in MIBC
At the 2026 ASCO Genitourinary Cancers Symposium, Matthew D. Galsky, MD, presented results from the phase 3 KEYNOTE-B15 study showing that perioperative enfortumab vedotin…
-
ASCO GI 2026: Encorafenib/Cetuximab Plus FOLFIRI Improves Response in BRAF V600E CRC
At the 2026 Gastrointestinal Cancers Symposium, BREAKWATER Cohort 3 delivered the clearest signal yet that encorafenib plus cetuximab can be paired with FOLFIRI (folinic…
-
FDA Closes Out 2025 With 16 Oncology Approvals in Six Weeks
The US Food and Drug Administration (FDA) closed out 2025 with 16 hematology/oncology approvals in just six weeks, marking one of the most active…
-
Oral Menin-Based Triplet Shows Strong Early Activity in ND AML
The phase II SAVE trial presented at the 2025 American Society of Hematology (ASH) Annual Meeting (Abstract 47) delivered early but compelling results from…
-
FDA Approves Liso-Cel for R/R MZL
On December 4, 2025, the US Food and Drug Administration (FDA) approved the CD19/CD3-directed CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with…
-
FDA Approves Epcoritamab with Rituximab and Lenalidomide for R/R FL
On November 18, 2025, the US Food and Drug Administration approved epcoritamab-bysp in combination with rituximab and lenalidomide for adult patients with relapsed or…
-
New Interchangeable Pertuzumab Biosimilar Approved for HER2-Positive Breast Cancer
On November 13, 2025, the US Food and Drug Administration approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta) for the treatment of…
-
Ziftomenib Approved for NPM1-Mutant R/R AML
On November 13, 2025, the US Food and Drug Administration approved the menin inhibitor ziftomenib (Komzifti) for adult patients with relapsed or refractory acute…
-
ESMO25: Neoadjuvant T-DXd Combo Tops Anthracycline Standard With Less Toxicity in HER2+ eBC
At the 2025 European Society for Medical Oncology (ESMO) Congress, Nadia Harbeck, MD, of the University of Munich, presented results of the phase 3…
-
Four-Year Median OS with Osimertinib/ Chemotherapy Combination in Advanced EGFR-Mutation Positive NSCLC
he final overall survival (OS) analysis from the FLAURA2 trial was presented during the International Association for the Study of Lung Cancer (IASLC) 2025…
-
FDA Approves Sunvozertinib for EGFR Exon 20 Insertion-Positive Metastatic NSCLC
On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib for patients with locally advanced or metastatic non-small…